Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7642278 Indazole benzimidazole compounds

Patent 7642278 was granted and assigned to Novartis on January, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7642278

Date of Patent

January 5, 2010

Patent Application Number

11261995

Date Filed

October 27, 2005

Patent Citations Received

‌

US Patent 12012401 Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide

‌

US Patent 11684615 Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors

‌

US Patent 11697649 Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof

‌

US Patent 11780823 Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors

‌

US Patent 11667632 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof

Patent Primary Examiner

‌

James O. Wilson

Patent abstract

Organic compounds having the structure I are provided where the variables have the values described herein.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7642278 Indazole benzimidazole compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API